A biopharmaceutical company developing nucleic acid drugs, including oligonucleotides, to reduce the expression of disease-promoting proteins or convert dysfunctional mutant proteins into functional proteins. The company is conducting clinical trials of drugs to treat Duchenne muscular dystrophy and Huntington's disease, which are expected to be effective in treating diseases that are considered difficult to treat.